| pubmed-article:15613909 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15613909 | lifeskim:mentions | umls-concept:C0019163 | lld:lifeskim |
| pubmed-article:15613909 | lifeskim:mentions | umls-concept:C0001758 | lld:lifeskim |
| pubmed-article:15613909 | lifeskim:mentions | umls-concept:C0596988 | lld:lifeskim |
| pubmed-article:15613909 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15613909 | pubmed:dateCreated | 2004-12-22 | lld:pubmed |
| pubmed-article:15613909 | pubmed:abstractText | A patient with stage IV non-Hodgkin's lymphoma and chronic hepatitis who was treated with chemotherapy and rituximab developed fatal reactivation of hepatitis B. High viral load titers of hepatitis B DNA were demonstrated. DNA sequencing analysis revealed the presence of the precore mutant strain. Hepatitis B reactivation in patients receiving rituxmab-based chemotherapy is reviewed and the role of precore mutant virus strains resulting in fatal complications is discussed. | lld:pubmed |
| pubmed-article:15613909 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15613909 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15613909 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15613909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15613909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15613909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15613909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15613909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15613909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15613909 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15613909 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15613909 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:15613909 | pubmed:issn | 0959-4973 | lld:pubmed |
| pubmed-article:15613909 | pubmed:author | pubmed-author:ZellJason AJA | lld:pubmed |
| pubmed-article:15613909 | pubmed:author | pubmed-author:Ignatius... | lld:pubmed |
| pubmed-article:15613909 | pubmed:author | pubmed-author:ChangJae CJC | lld:pubmed |
| pubmed-article:15613909 | pubmed:author | pubmed-author:YoonEugene... | lld:pubmed |
| pubmed-article:15613909 | pubmed:author | pubmed-author:HoefsJohn CJC | lld:pubmed |
| pubmed-article:15613909 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15613909 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:15613909 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15613909 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15613909 | pubmed:pagination | 83-5 | lld:pubmed |
| pubmed-article:15613909 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:meshHeading | pubmed-meshheading:15613909... | lld:pubmed |
| pubmed-article:15613909 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15613909 | pubmed:articleTitle | Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. | lld:pubmed |
| pubmed-article:15613909 | pubmed:affiliation | Division of Hematology/Oncology, Department of Medicine, College of Medicine, University of California Irvine, Irvine, CA, USA. jzell@uci.edu | lld:pubmed |
| pubmed-article:15613909 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15613909 | pubmed:publicationType | Case Reports | lld:pubmed |
